The Francis Crick Institute
34233964.pdf (1017.35 kB)

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab.

Download (1017.35 kB)
journal contribution
posted on 2021-07-20, 14:26 authored by James L Alexander, Hajir Ibraheim, Bhavisha Sheth, Jessica Little, Muhammad Saheb Khan, Camellia Richards, Nikki Hunter, Dharmisha Chauhan, Raguprakash Ratnakumaran, Kathleen McHugh, David J Pinato, Paul Nathan, Julia Choy, Shanthini M Crusz, Andrew Furness, Samra Turajlic, Lisa Pickering, James Larkin, Julian P Teare, Sophie Papa, Ally Speight, Anand Sharma, Nick Powell
INTRODUCTION: Immune checkpoint inhibitors (CPIs) have changed the treatment landscape for many cancers, but also cause severe inflammatory side effects including enterocolitis. CPI-induced enterocolitis is treated empirically with corticosteroids, and infliximab (IFX) is used in corticosteroid-refractory cases. However, robust outcome data for these patients are scarce. METHODS: We conducted a multicenter (six cancer centers), cohort study of outcomes in patients treated with IFX for corticosteroid-refractory CPI-induced enterocolitis between 2007 and 2020. The primary outcome was corticosteroid-free clinical remission (CFCR) with Common Terminology Criteria for Adverse Events (CTCAE) grade 0 for diarrhea at 12 weeks after IFX initiation. We also assessed cancer outcomes at 1 year using RECIST V1.1 criteria. RESULTS: 127 patients (73 male; median age 59 years) were treated with IFX for corticosteroid-refractory CPI-induced enterocolitis. Ninety-six (75.6%) patients had diarrhea CTCAE grade >2 and 115 (90.6%) required hospitalization for colitis. CFCR was 41.2% at 12 weeks and 50.9% at 26 weeks. In multivariable logistic regression, IFX-resistant enterocolitis was associated with rectal bleeding (OR 0.19; 95% CI 0.04 to 0.80; p=0.03) and absence of colonic crypt abscesses (OR 2.16; 95% CI 1.13 to 8.05; p=0.03). Cancer non-progression was significantly more common in patients with IFX-resistant enterocolitis (64.4%) as compared with patients with IFX-responsive enterocolitis (37.5%; p=0.013). CONCLUSION: This is the largest study to date reporting outcomes of IFX therapy in patients with corticosteroid-refractory CPI-induced enterocolitis. Using predefined robust endpoints, we have demonstrated that fewer than half of patients achieved CFCR. Our data also indicate that cancer outcomes may be better in patients developing prolonged and severe inflammatory side effects of CPI therapy.


Crick (Grant ID: 10988, Grant title: Turajlic FC001988) Cancer Research UK (Grant ID: 18176, Grant title: CRUK C50947/A18176)


Usage metrics

    The Francis Crick Institute



    Ref. manager